You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CTLA4-Ig

Showing 1 - 25 of 2,293
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Type 1 Diabetes, Diabetes, Type 1 Trial in Australia (Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®), Abatacept (CTLA4-Ig)

Recruiting
  • Type 1 Diabetes
  • Diabetes Mellitus, Type 1
  • Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
  • Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)
  • Westmead, New South Wales, Australia
  • +5 more
Feb 15, 2023

Giant Cell Arteritis Trial in Canada, United States (Abatacept, Placebo)

Recruiting
  • Giant Cell Arteritis
  • Rochester, Minnesota
  • +5 more
Jul 11, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Buffalo, East Hills, West Islip (biological, drug, other)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Abatacept
  • +3 more
  • Buffalo, New York
  • +2 more
Dec 22, 2022

Abnormal Glucose Tolerance, Type 1 Diabetes Trial in Canada, United States (CTLA4-Ig (Abatacept), Placebo)

Active, not recruiting
  • Abnormal Glucose Tolerance
  • Type 1 Diabetes
  • CTLA4-Ig (Abatacept)
  • Placebo
  • San Francisco, California
  • +16 more
Apr 13, 2022

Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis Trial in Worldwide

Recruiting
  • Granulomatosis With Polyangiitis (Wegener's)
  • +3 more
  • Los Angeles, California
  • +19 more
May 2, 2022

Systemic Lupus Erythematosus Arthritis Trial in Los Angeles, San Diego (abatacept also known as Orencia also known as CTLA4-Ig,

Terminated
Has Results
  • Systemic Lupus Erythematosus Arthritis
  • abatacept also known as Orencia also known as CTLA4-Ig
  • Placebo
  • Los Angeles, California
  • +1 more
May 11, 2021

Sickle Cell Disease, GVHD Trial in United States (Diphenhydramine, Acetaminophen, Methylprednisolone)

Active, not recruiting
  • Sickle Cell Disease
  • Graft Versus Host Disease
  • Washington, District of Columbia
  • +6 more
Aug 4, 2021

Type 1 Diabetes Trial in Canada, United States (CTLA-4 Ig, Placebo)

Completed
Has Results
  • Type 1 Diabetes Mellitus
  • CTLA-4 Ig
  • Placebo
  • Los Angeles, California
  • +12 more
Apr 27, 2020

CTLA4 Haploinsufficency, Chronic Cytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • CTLA4 Haploinsufficency
  • Chronic Cytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

CTLA-4 and LRBA Hereditary Deficiency

Completed
  • CTLA4 Haploinsufficiency
    • Montpellier, France
      Uhmontpellier
    Nov 12, 2021

    Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • SBRT, Fruquintinib, Cadonilimab
    • Wuhan, Hubei, China
      Cancer Center, Union Hospital, Tongji Medical College, Huazhong
    Feb 18, 2023

    Rheumatoid Arthritis, Rheumatic Diseases Trial in Leiden (Abatacept, Methotrexate)

    Completed
    • Rheumatoid Arthritis
    • Rheumatic Diseases
    • Leiden, Netherlands
      Leiden University Medical Center
    Aug 16, 2022

    NPC Trial in Guangzhou (Sintilimab, IBI310)

    Active, not recruiting
    • NPC
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 3, 2022

    Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Mar 31, 2022

    Advanced Lung Carcinoma, Advanced Malignant Solid Tumor, Malignant Adrenal Gland Tumor Trial in Houston (Anti-CTLA4 Monoclonal

    Recruiting
    • Advanced Lung Carcinoma
    • +16 more
    • Anti-CTLA4 Monoclonal Antibody BMS-986218
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 20, 2022

    Peripheral T-cell Lymphoma Trial in Beijing (AK104)

    Terminated
    • Peripheral T-cell Lymphoma
    • AK104
    • Beijing, Beiing, China
      Beijing Cancer Hospital
    Oct 17, 2022

    Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland

    Not yet recruiting
    • Locally Advanced Thyroid Gland Anaplastic Carcinoma
    • +2 more
    • Chicago, Illinois
    • +1 more
    Jul 7, 2022

    Health Volunteer Trial in Beijing (Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC

    Recruiting
    • Health Volunteer
    • Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
    • +9 more
    • Beijing, China
      Peking University People's Hospital
    Feb 15, 2022

    Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Atlanta

    Not yet recruiting
    • Castration-Sensitive Prostate Carcinoma
    • +2 more
    • Atlanta, Georgia
    • +1 more
    Feb 8, 2023

    Metastatic Soft-tissue Sarcoma Trial in United States (Cabozantinib, Nivolumab, Ipilimumab)

    Recruiting
    • Metastatic Soft-tissue Sarcoma
    • Stanford, California
    • +3 more
    Jan 10, 2023

    Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Oct 17, 2022

    Leptomeningeal Metastasis, NSCLC Stage IV, Melanoma Stage IV Trial in Geneva, St Gallen, Zurich (intrathecal nivolumab and

    Recruiting
    • Leptomeningeal Metastasis
    • +2 more
    • intrathecal nivolumab and intrathecal ipilimumab
    • Geneva, Switzerland
    • +2 more
    Dec 18, 2022

    Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • AK104 lenvatinib
    • AK104
    • Hangzhou, Zhejiang, China
      The first affilited hospital zhejiang university school of medci
    Oct 17, 2022